BIO’s View: Russian aggression demands more investment in medical countermeasures

Along with funding pandemic preparedness, “U.S. policymakers and lawmakers need to broaden their vision to include preparing for human-generated chemical, biological, radiological, and nuclear threats as well,” BIO President and CEO Dr. Michelle McMurry-Heath and former Sen. Joe Lieberman argue in a joint opinion piece published in STAT News today.

“Russia is creating the possibility of a chemical, biological, radiological, and nuclear (CBRN) nightmare. Its aggression against Ukraine makes it clear that American investment in innovative medical countermeasures is long overdue. U.S. policymakers must ensure that this country is as ready as it can be before the worst comes calling,” they say.

“Federal officials need to craft policies that make public-private cooperation profitable for the private sector and cost effective for the government. Through Project BioShield, BARDA (the Biomedical Advanced Research and Development Authority) has provided funding directly to companies doing research on medical countermeasures. This federal support needs to grow alongside the growth in CBRN threats.”

Read the full op-ed here.

About The Author

Scroll to Top